Bimatoprost for Hair Loss

Bimatoprost is a prescription prostaglandin analog best known in hair treatment for its ability to increase eyelash growth. Unlike many medications discussed in hair loss, bimatoprost has an FDA approved hair growth indication: bimatoprost ophthalmic solution 0.03 percent, marketed as Latisse, is approved for hypotrichosis of the eyelashes and can increase eyelash length, thickness and darkness.

That approval does not extend to the eyebrows or scalp.

Bimatoprost has also been studied off label for eyebrow hypotrichosis, eyelash loss caused by alopecia areata and several forms of scalp hair loss. Results vary substantially depending on where the medication is used and what condition is causing the hair loss.

The distinction is important. Evidence that bimatoprost grows eyelashes does not prove that the same 0.03 percent ophthalmic solution will meaningfully treat male pattern hair loss, female pattern hair loss or scalp alopecia areata. Eyelashes, eyebrows and scalp hair have different growth cycles and biological environments, and formulations developed for one site should not automatically be assumed to work at another.

As of 2026, the clearest role for bimatoprost remains eyelash growth. Its use elsewhere should be evaluated according to the specific diagnosis and evidence rather than simply describing it as a general hair growth medication.

What Is Bimatoprost?

Bimatoprost is a synthetic prostaglandin related compound originally developed to reduce elevated pressure inside the eye.

It has been used in ophthalmology to treat glaucoma and ocular hypertension. During ophthalmic treatment, increased eyelash growth became an obvious and reproducible effect.

That observation eventually led to development of bimatoprost 0.03 percent specifically for eyelash hypotrichosis. Latisse was approved by the FDA in 2008 to increase eyelash growth, including length, thickness and darkness.

How Does Bimatoprost Stimulate Hair Growth?

The exact mechanism responsible for bimatoprost induced hair growth has not been completely established.

FDA prescribing information states that eyelash growth is believed to occur primarily by increasing the percentage of follicles in the anagen, or active growth, phase and by increasing the duration of anagen.

Experimental research also suggests that bimatoprost can act directly on hair follicle structures, including cells within the dermal papilla.

The medication can also increase hair pigmentation, which helps explain why treated eyelashes may appear darker in addition to becoming longer and fuller.

This mechanism is very different from finasteride or dutasteride, which alter androgen metabolism, and from minoxidil, whose hair growth effects arise through different follicular and vascular signaling pathways.

Is Bimatoprost FDA Approved for Hair Loss?

Yes, but only for a very specific form of hair growth treatment.

Bimatoprost ophthalmic solution 0.03 percent is FDA approved for hypotrichosis of the eyelashes.

It is not FDA approved for:

• Male pattern hair loss
• Female pattern hair loss
• Scalp alopecia areata
• Eyebrow hypotrichosis
• Eyebrow alopecia areata
• Telogen effluvium
• Scarring alopecia

Use in those areas or conditions is off label or investigational.

That distinction becomes particularly important when compounded or experimental scalp formulations are marketed using the reputation of Latisse.

An FDA approved eyelash product does not make every bimatoprost formulation an FDA approved hair loss treatment.

How Effective Is Bimatoprost for Eyelash Growth?

The evidence for ordinary eyelash hypotrichosis is strong.

In the pivotal randomized study involving 278 adults, 78 percent of patients using bimatoprost 0.03 percent achieved at least a one grade improvement in overall eyelash prominence by week 16 compared with 18 percent receiving vehicle.

Digital analysis also demonstrated significant increases in eyelash length, fullness and darkness.

Improvement was gradual. Meaningful differences became evident after approximately two months, with greater improvement over the following several months.

Longer term randomized studies involving idiopathic and chemotherapy related eyelash hypotrichosis also demonstrated sustained benefit with continued treatment.

This is why eyelash hypotrichosis is fundamentally different from the other potential hair uses of bimatoprost. Here, there is both substantial clinical evidence and an FDA approved treatment indication.

How Is Latisse Supposed to Be Applied?

The FDA approved regimen is once nightly application to the skin of the upper eyelid margin at the base of the eyelashes using the supplied sterile applicator.

It is not supposed to be applied directly into the eye as an eyelash treatment, although accidental entry into the eye generally does not require rinsing.

It should not routinely be applied to the lower eyelid margin.

Excess solution should be blotted away because repeated contact with surrounding skin can cause unwanted hair growth.

Using more than the recommended amount or applying it more frequently has not been shown to produce greater eyelash growth.

How Long Does It Take to Work?

Eyelash improvement develops gradually.

Some changes may become noticeable after approximately eight weeks, while more substantial improvement usually develops over three to four months and can continue with longer treatment.

Bimatoprost does not permanently alter the eyelash follicle.

Once treatment is discontinued, the enhanced eyelashes gradually cycle out and the appearance moves back toward the pretreatment state.

Does Bimatoprost Have to Be Continued?

Yes, if the objective is to maintain the enhanced eyelash effect.

Bimatoprost does not permanently reprogram the follicle. When treatment stops, eyelash length, thickness, fullness and pigmentation generally return gradually toward baseline as the hairs complete their natural growth cycles.

The same principle would be expected when bimatoprost is successfully used off label on eyebrows or other hair bearing areas.

Does Bimatoprost Work for Eyebrows?

There is meaningful evidence that it can improve ordinary eyebrow hypotrichosis.

A large multicenter randomized double masked trial enrolled 357 adults with sparse eyebrows. Patients received bimatoprost 0.03 percent once daily, twice daily or vehicle for seven months.

By month seven, 83.9 percent of patients using bimatoprost twice daily and 77.1 percent using it once daily achieved at least a one grade improvement in eyebrow fullness compared with 43 percent receiving vehicle.

Objective measures of eyebrow fullness and darkness also improved.

The relatively high vehicle response is worth noting because the primary outcome involved a graded cosmetic assessment. However, the bimatoprost groups still performed significantly better than vehicle, and objective measures also supported treatment activity.

Once daily and twice daily treatment produced broadly similar results. Using the medication more often did not establish a clearly superior treatment strategy.

Importantly, this study excluded patients with alopecia areata. The results therefore should not automatically be applied to autoimmune eyebrow loss.

Is 0.03 Percent Better Than 0.01 Percent for Eyebrows?

Not clearly.

Randomized studies have shown eyebrow improvement with both 0.01 percent and 0.03 percent bimatoprost.

A split face study comparing the two concentrations found significant improvement in eyebrow density and diameter with both. There were no statistically significant differences between concentrations in those objective measurements, although patients tended to prefer the cosmetic result with 0.03 percent.

Another randomized study comparing 0.01 percent bimatoprost, 0.03 percent bimatoprost and 2 percent minoxidil found improvement with all three treatments without a statistically significant difference among them in the main eyebrow measurements.

The higher percentage therefore should not automatically be interpreted as a better treatment.

Is Bimatoprost Better Than Minoxidil for Eyebrows?

There is not enough evidence to make that conclusion.

A 2023 randomized trial involving 60 patients compared bimatoprost 0.03 percent, bimatoprost 0.01 percent and minoxidil 2 percent for eyebrow hypotrichosis.

All three groups improved significantly.

Although cosmetic satisfaction was greater in the 0.03 percent bimatoprost group, objective differences in eyebrow hair number and diameter between groups were not statistically significant.

That study was small and relatively short.

The appropriate conclusion is that both medications can stimulate eyebrow growth, not that bimatoprost has been established as universally superior.

What About Eyebrow Loss From Alopecia Areata?

This is a different question from ordinary sparse eyebrows.

Alopecia areata is an autoimmune disease. Simply stimulating a follicle does not necessarily overcome an active immune attack.

Most of the stronger eyebrow bimatoprost trials excluded patients with alopecia areata, so those studies cannot establish efficacy for autoimmune eyebrow loss.

Current 2026 alopecia areata guidance favors topical corticosteroids or topical calcineurin inhibitors for eyebrow alopecia areata and allows intralesional corticosteroid treatment by physicians experienced in that area.

There is currently insufficient evidence to establish bimatoprost as a standard treatment for eyebrow alopecia areata.

What About Eyelash Loss From Alopecia Areata?

Bimatoprost has a more established off label role for alopecia areata affecting the eyelashes, but responses remain inconsistent.

A retrospective study followed 41 patients with alopecia universalis who applied bimatoprost 0.03 percent to the eyelid margin for one year. Among those completing treatment, approximately 24 percent achieved complete eyelash regrowth, 19 percent had moderate regrowth and 27 percent experienced slight regrowth. Approximately 30 percent did not respond.

Other studies have produced less convincing results.

A later prospective study in patients with alopecia totalis or universalis found that bimatoprost could increase the length and thickness of eyelashes that were already present but did not induce new eyelash regrowth in patients without eyelashes at baseline.

The conflicting evidence is important. Bimatoprost can stimulate responsive eyelash follicles, but it does not directly treat the autoimmune disease responsible for alopecia areata.

The 2026 German S3 alopecia areata guideline nevertheless states that prostaglandin analogues can be offered off label for alopecia areata involving the eyelashes.

This is an important distinction from scalp disease.

Can Children With Alopecia Areata Use Bimatoprost for Eyelashes?

Bimatoprost has been studied in children and adolescents.

The current Latisse prescribing information includes a randomized pediatric study involving patients ages 5 to 17 who had eyelash loss after chemotherapy, alopecia areata or ordinary adolescent hypotrichosis.

The strongest treatment response occurred in adolescents with ordinary hypotrichosis.

Among the very small subgroup with alopecia areata, 4 of 9 bimatoprost treated patients improved by at least one eyelash grade compared with 2 of 6 receiving vehicle. The confidence interval around the treatment difference was extremely wide.

That is far too little evidence to establish convincing efficacy for pediatric alopecia areata.

No new safety signal was identified in the trial, but treatment in a child with autoimmune eyelash loss should still be individualized.

Does Bimatoprost Work for Scalp Alopecia Areata?

Small studies have reported hair regrowth with topical bimatoprost in localized scalp alopecia areata, but current guideline evidence does not support its use for this purpose.

Some studies have compared bimatoprost with topical corticosteroids and reported encouraging results. Others have found no significant difference between treatments. These studies have generally involved small patient populations, short treatment periods and varying study designs.

The 2026 German S3 alopecia areata guideline reviewed the available evidence and makes a strong recommendation that prostaglandin F2 alpha analogues should not be offered for scalp alopecia areata in children, adolescents or adults.

That conclusion is more important clinically than isolated small positive trials.

Bimatoprost therefore should not currently be presented as an established or recommended scalp treatment for alopecia areata.

What About Fractional Laser With Bimatoprost?

Several small studies have investigated fractional carbon dioxide laser treatment followed by bimatoprost in an effort to increase drug delivery into areas of localized alopecia areata.

Some have reported greater regrowth with the combination than with bimatoprost or laser treatment alone.

These findings are interesting as emerging research, but they do not establish laser assisted bimatoprost delivery as standard treatment for scalp alopecia areata.

They also do not override current guideline recommendations against prostaglandin analogues for scalp AA.

What About Microneedling With Bimatoprost?

Microneedling deliberately disrupts the skin barrier and could substantially change how much bimatoprost penetrates into the scalp.

The pharmacokinetics and long term safety of compounded or ophthalmic bimatoprost applied immediately after scalp microneedling have not been adequately established.

A systemic exposure profile obtained from intact skin or ophthalmic administration should not be assumed to apply after deliberate barrier disruption.

The AHLA does not consider routine home microneedling followed immediately by bimatoprost an established treatment strategy.

Does Bimatoprost Work for Male Pattern Hair Loss?

This remains investigational.

Laboratory research has demonstrated that bimatoprost can stimulate isolated human scalp hair follicles and has identified bimatoprost responsive receptors within follicular structures.

Those findings led to multiple Phase II development programs evaluating topical bimatoprost formulations for androgenetic alopecia in men.

Those clinical development programs were completed, but no bimatoprost scalp formulation progressed to an FDA approved treatment for male androgenetic alopecia, and no Phase III program established an approved scalp indication.

It is important not to infer from that history precisely why development did not progress. The documented conclusion is simply that bimatoprost has been studied clinically for scalp androgenetic alopecia but has not become an established or approved treatment.

What About the New 2026 Bimatoprost Scalp Study?

Interest in bimatoprost for androgenetic alopecia has not completely disappeared.

A 2026 pharmacokinetic study evaluated two 1 percent bimatoprost formulations applied once daily to the scalps of 11 men with androgenetic alopecia for 14 days.

Skin biopsies demonstrated that both formulations delivered bimatoprost into deeper scalp tissue, including subcutaneous tissue around the depth at which the hair papilla is found.

The tissue concentrations exceeded levels associated with maximal hair growth in the investigators’ isolated human hair follicle laboratory model.

That distinction is critical.

A concentration capable of stimulating an isolated follicle in a laboratory experiment is not the same as a concentration that has been proven to reverse miniaturization or produce cosmetically significant scalp regrowth in a person.

The 2026 study was a pharmacokinetic and short term tolerability study. It was not an efficacy trial. It did not establish increased hair counts, reversal of follicular miniaturization or cosmetically meaningful regrowth.

It is also critical to recognize the concentration difference. A 1 percent research formulation contains more than 30 times the bimatoprost concentration of Latisse 0.03 percent.

The study therefore does not establish that applying ordinary Latisse to the scalp will treat androgenetic alopecia.

Does a Compounded 1 Percent Bimatoprost Product Have the Same Evidence?

No.

Evidence that a specifically developed research formulation successfully delivered 1 percent bimatoprost into deeper scalp tissue does not validate every compounded 1 percent bimatoprost scalp product.

Vehicle, solubility, stability, application volume, penetration characteristics and manufacturing can all influence how much medication reaches the relevant follicular structures.

Two products can contain the same percentage of bimatoprost and still produce different local tissue exposure.

The 2026 pharmacokinetic research therefore supports continued investigation of properly formulated scalp bimatoprost. It should not be used as blanket validation for arbitrary compounded high concentration products.

Does Bimatoprost Work for Female Pattern Hair Loss?

There is no FDA approved role for bimatoprost in female pattern hair loss.

Phase II clinical development programs evaluated topical bimatoprost formulations in women with female pattern hair loss and compared them with vehicle and topical minoxidil.

Those studies did not result in an FDA approved scalp treatment, and the available published reporting does not provide the kind of comprehensive modern efficacy evidence available for established treatments such as topical minoxidil.

There is currently no well established bimatoprost dose, concentration or formulation for female pattern hair loss.

The new 2026 scalp pharmacokinetic study involved men only and therefore does not establish efficacy, dosing or safety for women with female pattern hair loss.

Should Someone Put Latisse on the Scalp?

The evidence does not support treating Latisse 0.03 percent as an established scalp hair loss medication.

The FDA approved eyelash product was designed for application to a very small area of the upper eyelid margin.

Experimental scalp development has involved different concentrations and specially developed formulations, including concentrations far greater than 0.03 percent.

Scalp surface area, follicular delivery, formulation stability, penetration and systemic exposure are all different questions.

Evidence from eyelashes cannot simply be transferred to the scalp.

What Side Effects Can Bimatoprost Cause?

When Latisse 0.03 percent was used according to the approved eyelash regimen, the most common adverse effects in clinical trials included eye itching, conjunctival redness and skin hyperpigmentation. These occurred in approximately 3 to 4 percent of patients.

Other reported effects included:

• Eyelid or surrounding skin pigmentation
• Eye irritation
• Dry eye symptoms
• Redness around the eyelid
• Eyelid swelling
• Increased tearing
• Allergic reactions
• Rash
• Eyelash breakage
• Abnormal eyelash direction
• Blurred vision

The safety profile may differ when bimatoprost is placed on the eyebrows or over large areas of scalp because those uses have not undergone the same FDA review.

Can Bimatoprost Darken the Eyelid Skin?

Yes.

Bimatoprost can increase pigmentation of the eyelid and surrounding skin.

Periorbital skin pigmentation may increase while treatment continues and has been reported to improve after the medication is discontinued in most patients.

Pigmentation changes around the eye should be distinguished from iris pigmentation, which carries a different implication.

Can Bimatoprost Permanently Change Eye Color?

Potentially, yes.

Bimatoprost can increase brown pigmentation of the iris.

Current prescribing information warns that increased iris pigmentation is likely to be permanent.

The change occurs because bimatoprost increases melanin within iris melanocytes rather than increasing the number of pigment cells.

Iris color change may take months or years to become apparent.

This risk is best documented when bimatoprost is placed directly into the eye during ophthalmic treatment. The exact incidence resulting from careful upper eyelid margin application for eyelash growth has not been established well enough to tell consumers that the risk is zero.

What Is Prostaglandin Associated Periorbitopathy?

Long term exposure to prostaglandin related medications can produce characteristic changes around the eyes collectively known as prostaglandin associated periorbitopathy.

Changes can include:

• Loss of fat around the eye
• Deepening of the upper eyelid sulcus
• A more hollow or sunken appearance
• Eyelid skin tightening
• Eyelid ptosis or drooping
• Changes in the overall contour of the eyelid and orbit

Current Latisse prescribing information specifically includes postmarketing reports of periorbital fat atrophy, skin tightening, deepening of the eyelid sulcus and eyelid ptosis.

The strongest evidence and highest reported frequencies for prostaglandin associated periorbitopathy come from glaucoma patients receiving chronic direct ocular prostaglandin therapy. Those frequency estimates should not be transferred to people applying Latisse to the eyelid margin for cosmetic eyelash growth.

The actual incidence with cosmetic eyelid margin use is not well established. Published safety reviews have raised concern that the clinical trials used to evaluate eyelash growth were not designed to detect subtle changes in periorbital fat and eyelid anatomy reliably.

Some periocular changes may improve after bimatoprost is discontinued, but complete reversal cannot be guaranteed.

Patients using bimatoprost around the eye should know that progressive hollowing, deepening of the upper eyelid crease, eyelid drooping or other changes in orbital appearance deserve medical evaluation.

Can Bimatoprost Lower Eye Pressure?

Yes.

Bimatoprost was originally developed specifically because it lowers intraocular pressure.

Clinical trials of Latisse found some reduction in intraocular pressure, although the magnitude was not considered clinically concerning in otherwise appropriate patients.

However, patients already using bimatoprost, latanoprost or another prostaglandin related medication for glaucoma or ocular hypertension should not add Latisse without discussing it with their ophthalmologist.

Exposure to more than one dose of this drug class daily can interfere with the desired pressure lowering response.

People with a history of abnormal intraocular pressure should therefore be medically supervised.

Who Needs Extra Caution Around the Eyes?

Additional ophthalmic consideration is appropriate in patients with:

• Glaucoma or ocular hypertension
• Active uveitis or other intraocular inflammation
• A history of macular edema
• Aphakia, meaning absence of the natural lens
• Certain patients with artificial lenses after cataract surgery
• Recent eye surgery
• Significant chronic ocular surface disease
• Previous reactions to prostaglandin analogues

Bimatoprost can exacerbate intraocular inflammation in susceptible patients, and macular edema has been reported with ophthalmic bimatoprost.

A physician prescribing treatment around the eye should know about significant ophthalmic history.

Can Bimatoprost Cause Hair Growth Where It Is Not Wanted?

Yes.

Repeated contact with surrounding skin can stimulate hair growth outside the intended treatment area.

This is why the FDA instructions recommend blotting excess Latisse from the eyelid margin.

The same issue matters when bimatoprost is used off label on eyebrows. Medication that repeatedly spreads beyond the intended eyebrow border could stimulate unwanted hairs in adjacent skin.

Application precision matters.

What About Contact Lenses?

Latisse contains benzalkonium chloride, a preservative that can be absorbed by soft contact lenses and may discolor them.

Contact lenses should be removed before application and may generally be reinserted 15 minutes later.

This instruction applies to the FDA approved Latisse formulation. A compounded bimatoprost preparation may contain a different vehicle or preservative system.

Can the Bottle or Applicator Become Contaminated?

Yes.

The FDA approved product is supplied with sterile single use applicators.

A new applicator should be used for each eye, and the bottle tip should not touch the eye, fingers or other surfaces.

Contaminated ophthalmic products can cause serious eye infections, including bacterial keratitis.

This is another reason not to improvise eyelash application techniques or transfer ophthalmic medication into unsterile cosmetic containers.

What About Pregnancy?

There are no adequate controlled studies of Latisse use during pregnancy.

Postmarketing human experience has not demonstrated an increased risk of major birth defects or miscarriage, but the available human data are limited.

Animal studies at systemic exposures substantially higher than human ophthalmic exposure produced pregnancy loss and other reproductive effects.

Current labeling therefore states that bimatoprost should be used during pregnancy only when the potential benefit justifies the potential fetal risk.

Because eyelash and eyebrow enhancement are elective treatments, many physicians may reasonably choose to avoid cosmetic bimatoprost during pregnancy even though human evidence has not established major fetal harm.

Scalp use creates additional uncertainty because systemic exposure from larger treatment areas and experimental formulations is not as well characterized as approved eyelid margin use.

What About Breastfeeding?

It is not known whether the small systemic exposure produced by topical Latisse results in detectable bimatoprost in human milk.

Bimatoprost has been found in the milk of lactating animals after much higher systemic exposure.

Current prescribing information recommends weighing the developmental and health benefits of breastfeeding against the mother’s need for treatment and any potential risk to the infant.

For elective cosmetic eyelash or eyebrow treatment, a breastfeeding patient should discuss whether treatment is necessary rather than assuming that topical application guarantees zero infant exposure.

Is Systemic Absorption Significant?

The available pharmacokinetic data demonstrate very low and short lived systemic exposure after direct ocular administration of bimatoprost 0.03 percent.

In the pharmacokinetic study included in the prescribing information, one drop of bimatoprost 0.03 percent was placed directly into both eyes once daily for two weeks. Blood concentrations peaked within approximately 10 minutes and fell below the assay detection limit in most participants within approximately 90 minutes. There was no significant systemic drug accumulation over time.

That study did not use the cosmetic Latisse technique of applying medication only to the upper eyelid margin.

The finding is nevertheless useful in demonstrating that systemic exposure from ophthalmic 0.03 percent bimatoprost can be very low. It should not be interpreted as proof that all other topical uses produce the same exposure.

In particular, these data cannot automatically be extrapolated to 1 percent scalp formulations, large scalp treatment areas, compounded penetration enhancing vehicles, damaged skin or treatment immediately after procedures that disrupt the skin barrier.

Is Bimatoprost a Treatment for Telogen Effluvium?

No established role exists.

Telogen effluvium is generally managed by identifying and addressing the trigger responsible for abnormal hair cycling.

Although bimatoprost can influence follicular growth phase biology, there is no established evidence base supporting routine bimatoprost treatment for telogen effluvium.

A patient with diffuse shedding should first receive an accurate diagnosis.

What Should Someone Ask Before Using Bimatoprost for Hair Growth?

Useful questions include:

• What type of hair loss am I actually treating?
• Is this FDA approved for the area where I am being asked to use it?
• Am I using FDA approved Latisse or a compounded formulation?
• What concentration am I using?
• Is there clinical evidence for that specific concentration and treatment site?
• If I have eyebrow loss, is it ordinary hypotrichosis or alopecia areata?
• If I have eyelash alopecia areata, am I also treating the autoimmune disease itself?
• How long should treatment be used before judging the response?
• What happens when treatment is discontinued?
• Could the medication affect my eye pressure?
• Do I have glaucoma, uveitis, macular edema or another eye condition that matters?
• What should I watch for around the eyelids or iris?
• Could it cause unwanted hair growth outside the treatment area?
• If this is being prescribed for my scalp, what evidence supports the specific formulation?
• Is the formulation being prescribed actually the one studied in published research?
• Why is bimatoprost being selected instead of an established treatment for my diagnosis?

Those questions become particularly important when the medication is being prescribed outside its FDA approved eyelash indication.

The AHLA Perspective

Bimatoprost is a genuine hair growth medication, but its effectiveness needs to be understood in the correct anatomical and clinical context.

For eyelash hypotrichosis, the evidence is strong. Bimatoprost 0.03 percent is FDA approved, has been evaluated in large randomized trials and reliably increases eyelash length, thickness and darkness in many patients.

For ordinary eyebrow hypotrichosis, the evidence is also encouraging. Large controlled studies demonstrate that bimatoprost can increase eyebrow fullness and pigmentation. That use remains off label.

Alopecia areata is different.

Bimatoprost can stimulate responsive eyelash follicles, and the 2026 German S3 guideline allows prostaglandin analogues to be considered off label for alopecia areata involving the eyelashes. But the medication does not treat the underlying autoimmune disease, responses are inconsistent and it should not be presented as equivalent to systemic disease modifying treatment when alopecia areata is severe.

The scalp presents an even larger distinction.

Although small studies of scalp alopecia areata have reported encouraging results, current 2026 guideline recommendations state that prostaglandin analogues should not be offered for scalp alopecia areata.

Androgenetic alopecia remains investigational as well. Bimatoprost has stimulated human scalp follicles in laboratory studies and has been evaluated in multiple clinical development programs for male and female pattern hair loss. Those programs did not establish an FDA approved scalp treatment.

The new 2026 research involving 1 percent scalp formulations is scientifically interesting because it demonstrates that specially formulated bimatoprost can reach deeper follicular tissue. It does not yet demonstrate hair regrowth in patients.

A patient should therefore not look at the success of Latisse and assume that applying the same 0.03 percent ophthalmic solution across a thinning scalp is an established treatment for male or female pattern hair loss.

Nor should evidence involving one experimental 1 percent scalp formulation be used to validate every compounded 1 percent bimatoprost product. Concentration alone does not determine follicular exposure. Vehicle, stability, penetration and manufacturing matter.

Safety also deserves more attention than the phrase “eyelash growth serum” sometimes suggests. Bimatoprost is an ophthalmic prostaglandin related medication capable of altering pigmentation, intraocular pressure and periocular tissues. Postmarketing labeling recognizes periorbital fat atrophy, deepening of the eyelid sulcus and eyelid ptosis in addition to irritation and pigmentation changes.

The objective should not be to put bimatoprost anywhere hair is missing simply because it can stimulate eyelashes.

The objective is to identify the cause of hair loss, understand whether meaningful evidence exists for bimatoprost at that particular anatomical site, use an appropriate formulation and balance the expected benefit against the local and ocular risks.

Used for: Male Pattern Baldness, Female Pattern Baldness

Selected References

1. AbbVie Inc. Latisse (bimatoprost ophthalmic solution) 0.03% Full Prescribing Information. Revised July 2024. DailyMed Prescribing Information
2. Smith S, Fagien S, Whitcup SM, et al. Eyelash Growth in Subjects Treated With Bimatoprost: A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study. J Am Acad Dermatol. 2012;66:801-806. doi:10.1016/j.jaad.2011.06.005. PubMed
3. Carruthers J, Beer K, Carruthers A, et al. Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis. Dermatol Surg. 2016;42:608-617. doi:10.1097/DSS.0000000000000755. PubMed
4. Suchonwanit P, Harnchoowong S, Chanasumon N, Sriphojanart T. Comparison of the Efficacy and Safety of Using 0.01% Versus 0.03% Bimatoprost for the Treatment of Eyebrow Hypotrichosis: A Randomized, Double-Blind, Split-Face, Comparative Study. J Cosmet Dermatol. 2020;19:714-719. doi:10.1111/jocd.13079. PubMed
5. Zaky MS, Hashem OA, Mahfouz SM, Elsaie ML. Comparative Study of the Efficacy and Safety of Topical Minoxidil 2% Versus Topical Bimatoprost 0.01% Versus Topical Bimatoprost 0.03% in Treatment of Eyebrow Hypotrichosis: A Randomized Controlled Trial. Arch Dermatol Res. 2023;315:2635-2641. doi:10.1007/s00403-023-02679-2. PubMed
6. Ojeda Vila T, Camacho Martinez FM. Bimatoprost in the Treatment of Eyelash Universalis Alopecia Areata. Int J Trichology. 2010;2:86-88. doi:10.4103/0974-7753.77511. PubMed
7. Blume-Peytavi U, Constantinou A, Tomova-Simitchieva T, et al. S3 Guideline Diagnostics and Therapy in Alopecia Areata, Part 2: Therapy, Psychosocial and Cosmetic Support. J Dtsch Dermatol Ges. 2026;24:e1155-e1177. doi:10.1111/ddg.70130x. Guideline
8. Khajeh Pour M, et al. Local Pharmacokinetics and Tolerability of Topically Applied Bimatoprost to the Scalp of Male Patients With Androgenetic Alopecia. Clin Transl Sci. 2026. doi:10.1111/cts.70710. PubMed
9. Steinsapir KD, Steinsapir SMG. Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products. Dermatol Surg. 2021;47:658-665. doi:10.1097/DSS.0000000000002928. PubMed